122 related articles for article (PubMed ID: 37963445)
1. QTc Interval Prolongation Is Independently Associated with FGF23 and Predicts Mortality in Predialysis Chronic Kidney Disease.
Sikaneta T; Ho N; Bellasi A; Mahdavi S; Taskapan H; Svendrovski A; Makanjee B; Roberts J; Wu G; Nathoo B; Tam P
Cardiorenal Med; 2024; 14(1):45-57. PubMed ID: 37963445
[TBL] [Abstract][Full Text] [Related]
2. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
Mitsnefes MM; Betoko A; Schneider MF; Salusky IB; Wolf MS; Jüppner H; Warady BA; Furth SL; Portale AA
Clin J Am Soc Nephrol; 2018 Jan; 13(1):45-52. PubMed ID: 29025789
[TBL] [Abstract][Full Text] [Related]
3. Impact of left ventricular hypertrophy on QT prolongation and associated mortality.
Haugaa KH; Bos JM; Borkenhagen EJ; Tarrell RF; Morlan BW; Caraballo PJ; Ackerman MJ
Heart Rhythm; 2014 Nov; 11(11):1957-65. PubMed ID: 24956189
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.
Jovanovich A; Ix JH; Gottdiener J; McFann K; Katz R; Kestenbaum B; de Boer IH; Sarnak M; Shlipak MG; Mukamal KJ; Siscovick D; Chonchol M
Atherosclerosis; 2013 Nov; 231(1):114-9. PubMed ID: 24125420
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor 23 (FGF23) induces ventricular arrhythmias and prolongs QTc interval in mice in an FGF receptor 4-dependent manner.
Graves JM; Vallejo JA; Hamill CS; Wang D; Ahuja R; Patel S; Faul C; Wacker MJ
Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2283-H2294. PubMed ID: 33929896
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
Portale AA; Wolf MS; Messinger S; Perwad F; Jüppner H; Warady BA; Furth SL; Salusky IB
Clin J Am Soc Nephrol; 2016 Nov; 11(11):1989-1998. PubMed ID: 27561289
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
De Jong MA; Eisenga MF; van Ballegooijen AJ; Beulens JWJ; Vervloet MG; Navis G; Gansevoort RT; Bakker SJL; De Borst MH
Nephrol Dial Transplant; 2021 Jan; 36(1):121-128. PubMed ID: 32124925
[TBL] [Abstract][Full Text] [Related]
8. Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension.
Paoletti E; De Nicola L; Gabbai FB; Chiodini P; Ravera M; Pieracci L; Marre S; Cassottana P; Lucà S; Vettoretti S; Borrelli S; Conte G; Minutolo R
Clin J Am Soc Nephrol; 2016 Feb; 11(2):271-9. PubMed ID: 26668021
[TBL] [Abstract][Full Text] [Related]
9. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D
Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731
[TBL] [Abstract][Full Text] [Related]
10. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients.
Hsu HJ; Wu MS
Am J Med Sci; 2009 Feb; 337(2):116-22. PubMed ID: 19214027
[TBL] [Abstract][Full Text] [Related]
12. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.
Mirza MA; Larsson A; Melhus H; Lind L; Larsson TE
Atherosclerosis; 2009 Dec; 207(2):546-51. PubMed ID: 19524924
[TBL] [Abstract][Full Text] [Related]
13. Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease.
Sinha MD; Turner C; Booth CJ; Waller S; Rasmussen P; Goldsmith DJ; Simpson JM
Pediatr Nephrol; 2015 Oct; 30(10):1843-52. PubMed ID: 25975437
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic Fatty Liver Disease Is Related to Abnormal Corrected QT Interval and Left Ventricular Hypertrophy in Chinese Male Steelworkers.
Hung WC; Yu TH; Wu CC; Lee TL; Tang WH; Chen CC; Lu IC; Chung FM; Lee YJ; Hsu CC
Int J Environ Res Public Health; 2022 Nov; 19(21):. PubMed ID: 36361436
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients.
Sarmento-Dias M; Santos-Araújo C; Poínhos R; Oliveira B; Silva IS; Silva LS; Sousa MJ; Correia F; Pestana M
Clin Nephrol; 2016 Mar; 85(3):135-41. PubMed ID: 26833300
[TBL] [Abstract][Full Text] [Related]
16. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension.
Rich JD; Thenappan T; Freed B; Patel AR; Thisted RA; Childers R; Archer SL
Int J Cardiol; 2013 Aug; 167(3):669-76. PubMed ID: 22459397
[TBL] [Abstract][Full Text] [Related]
17. Prolonged corrected QT interval is predictive of future stroke events even in subjects without ECG-diagnosed left ventricular hypertrophy.
Ishikawa J; Ishikawa S; Kario K
Hypertension; 2015 Mar; 65(3):554-60. PubMed ID: 25534703
[TBL] [Abstract][Full Text] [Related]
18. FGF23 in hemodialysis patients is associated with left ventricular hypertrophy and reduced ejection fraction.
Nielsen TL; Plesner LL; Warming PE; Mortensen OH; Iversen KK; Heaf JG
Nefrologia (Engl Ed); 2019; 39(3):258-268. PubMed ID: 30723045
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease.
Nitta K; Iimuro S; Imai E; Matsuo S; Makino H; Akizawa T; Watanabe T; Ohashi Y; Hishida A
Clin Exp Nephrol; 2013 Oct; 17(5):730-742. PubMed ID: 23318981
[TBL] [Abstract][Full Text] [Related]
20. FGF23 induces left ventricular hypertrophy.
Faul C; Amaral AP; Oskouei B; Hu MC; Sloan A; Isakova T; Gutiérrez OM; Aguillon-Prada R; Lincoln J; Hare JM; Mundel P; Morales A; Scialla J; Fischer M; Soliman EZ; Chen J; Go AS; Rosas SE; Nessel L; Townsend RR; Feldman HI; St John Sutton M; Ojo A; Gadegbeku C; Di Marco GS; Reuter S; Kentrup D; Tiemann K; Brand M; Hill JA; Moe OW; Kuro-O M; Kusek JW; Keane MG; Wolf M
J Clin Invest; 2011 Nov; 121(11):4393-408. PubMed ID: 21985788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
